Alkem Laboratories Limited
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
What Alkem files
- Others96
- Investor Meet62
- Updates42
- Important22
- Board Meeting11
- PPTs11
Alkem Laboratories' Board approved setting up a new manufacturing block at its Baddi facility. This expansion involves an investment of up to INR 75 Cr, enhancing operational capacity.
Alkem's Daman facility inspection status is now Official Action Indicated (OAI) by the FDA. The company continues US market supply and is working to achieve full compliance.
Alkem Labs' 52nd Annual General Meeting is scheduled for August 27. The Annual Report for FY25-26 is accessible online, with web-links dispatched to shareholders without registered emails.
Alkem Labs' FY26 BRSR shows robust environmental performance with 15% GHG and 22% energy reduction. Turnover was ₹9,664 Cr. No fines or corruption cases reported. Noteworthy were 36 voluntary and 8 forced product recalls.
Alkem's subsidiary, Alkem Medtech, completed the acquisition of a 51-55% stake in Switzerland-based Occlutech Holding AG. Occlutech is now a step-down subsidiary, expanding Alkem's global footprint.